Coya Therapeutics, Inc. (COYA) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Coya Therapeutics reported revenue of $7.9M, up 123.6% from $3.6M the year before. Net income was -$21.2M (a -267.1% net margin), or -$1.27 per diluted share. Operating margin was -283.9%. Operating activities generated -$10.7M of cash. At fiscal year end, Coya Therapeutics held $50.0M in total assets against $6.9M in total liabilities, including $46.8M of cash and equivalents.
Open the full interactive Coya Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Coya Therapeutics Key Stats
| Share Price | $4.47 |
|---|---|
| Market Cap | $105.0M |
| Revenue YoY Growth | +123.6% |
| 52-Week Range | $3.78 – $7.36 |
| Shares Outstanding | 23.5 million (basic, 2026 Q2) |
Coya Therapeutics Income Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $6.0M | $3.6M | $7.9M |
| Operating Income | -$9.8M | -$7.9M | -$17.2M | -$22.6M |
| Pre-Tax Income | -$12.2M | -$7.3M | -$15.6M | -$21.2M |
| Income Tax | — | $723,852 | -$720,287 | $3,089 |
| Net Income | -$12.2M | -$8.0M | -$14.9M | -$21.2M |
| Diluted EPS | -$4.73 | -$0.79 | -$0.98 | -$1.27 |
Coya Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $3.6M | $4.0M | $251,147 | $243,745 |
| Net Income | -$2.1M | -$5.7M | -$7.2M | -$6.6M |
| Diluted EPS | -$0.13 | -$0.34 | -$0.32 | -$0.28 |
Coya Therapeutics Balance Sheet
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash & Equivalents | $5.9M | $32.6M | $38.3M | $46.8M |
| Current Assets | $7.2M | $41.2M | $44.3M | $49.9M |
| Total Assets | $8.4M | $41.3M | $44.3M | $50.0M |
| Current Liabilities | $3.8M | $5.1M | $3.8M | $5.9M |
| Total Long-Term Debt | $13.0M | — | — | — |
| Total Liabilities | $16.8M | $5.6M | $4.8M | $6.9M |
| Shareholders' Equity | -$8.4M | $35.6M | $39.6M | $43.0M |
Coya Therapeutics Cash Flow Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash From Operations | -$7.2M | -$11.2M | -$10.3M | -$10.7M |
| Cash From Investing | -$525,000 | -$543,186 | -$25,000 | -$1.2M |
| Cash From Financing | $9.4M | $38.4M | $16.0M | $20.4M |
Figures from Coya Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Coya Therapeutics financials page for every line item.
Coya Therapeutics Company Profile
| Ticker | COYA |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Houston, Texas |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001835022 |
Frequently Asked Questions
What was Coya Therapeutics' revenue in fiscal 2025?
Coya Therapeutics (COYA) reported revenue of $7.9M for fiscal 2025.
What is Coya Therapeutics' annual revenue history?
Coya Therapeutics' annual revenue by fiscal year: 2022: $0; 2023: $6.0M; 2024: $3.6M; 2025: $7.9M.
What was Coya Therapeutics' net income in fiscal 2025?
Coya Therapeutics reported net income of -$21.2M for fiscal 2025.
What was Coya Therapeutics' earnings per share (EPS) in fiscal 2025?
Coya Therapeutics' diluted EPS was -$1.27 for fiscal 2025 (adjusted for any later stock splits).
What was Coya Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Coya Therapeutics reported revenue of $243,745.
How many shares of Coya Therapeutics are outstanding?
Coya Therapeutics reported a weighted average of 23.5 million basic shares outstanding in 2026 Q2.
What is Coya Therapeutics' market cap?
Based on its latest closing price, Coya Therapeutics (COYA) has a market capitalization of about $105.0M.
When does Coya Therapeutics' fiscal year end?
Coya Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Coya Therapeutics headquartered?
Coya Therapeutics lists its business address in Houston, Texas in its SEC filings.